造血细胞移植和细胞治疗受者COVID-19管理指南

IF 4.3 Q1 Medicine

Biology of Blood and Marrow Transplantation Pub Date : 2020-11-01 DOI:10.1016/j.bbmt.2020.07.027

Alpana Waghmare , Maheen Z. Abidi , Michael Boeckh , Roy F. Chemaly , Sanjeet Dadwal , Zeinab El Boghdadly , Mini Kamboj , Genovefa A. Papanicolaou , Steven A. Pergam , Zainab Shahid

{"title":"造血细胞移植和细胞治疗受者COVID-19管理指南","authors":"Alpana Waghmare , Maheen Z. Abidi , Michael Boeckh , Roy F. Chemaly , Sanjeet Dadwal , Zeinab El Boghdadly , Mini Kamboj , Genovefa A. Papanicolaou , Steven A. Pergam , Zainab Shahid","doi":"10.1016/j.bbmt.2020.07.027","DOIUrl":null,"url":null,"abstract":"<div><p>There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 1983-1994"},"PeriodicalIF":4.3000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.027","citationCount":"62","resultStr":"{\"title\":\"Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients\",\"authors\":\"Alpana Waghmare , Maheen Z. Abidi , Michael Boeckh , Roy F. Chemaly , Sanjeet Dadwal , Zeinab El Boghdadly , Mini Kamboj , Genovefa A. Papanicolaou , Steven A. Pergam , Zainab Shahid\",\"doi\":\"10.1016/j.bbmt.2020.07.027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.</p></div>\",\"PeriodicalId\":9165,\"journal\":{\"name\":\"Biology of Blood and Marrow Transplantation\",\"volume\":\"26 11\",\"pages\":\"Pages 1983-1994\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.027\",\"citationCount\":\"62\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biology of Blood and Marrow Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1083879120304602\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology of Blood and Marrow Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1083879120304602","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 62

摘要

目前，关于造血细胞移植和细胞治疗受者2019冠状病毒病(COVID-19)的流行病学、临床表现和最佳管理的数据有限。鉴于其他呼吸道病毒的经验，我们预计患者可能会出现严重的临床疾病，因此为全国的癌症中心提供以下一般原则。这些指南是由美国移植和细胞治疗学会传染病特别兴趣小组的成员制定的。具体做法可能因当地流行病学和检测能力而异，本文件提供的指导可能会随着获得新信息而改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

查看原文本刊更多论文

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biology of Blood and Marrow Transplantation 医学-免疫学

CiteScore

6.60

自引率

0.00%

发文量

1061

审稿时长

3-6 weeks

期刊介绍： Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.